NegEnt: A cannabidiol-based herbal medicine theoretical aspects, pharmacology, clinical and research perspectives, economic and social implications

Abstract

The article describes a research project that included the conception, development, testing and dissemination of a new drug, based on cannabidiol and called NegEnt (registered name and trademark). In this contribution, the author fully describes a new herbal medicine that was developed and how it can be used for significant progress on various treatments for different conditions in psychiatry, neurology, and medicine. It also presents completed work for new herbal medicines at affordable costs worldwide. The clinical research program launched and the organizational and legal solutions identified are described to scientifically evaluate in accordance with a single case research study design. NegEnt's pharmacokinetics, bioavailability, pharmacodynamics, therapeutic efficacy, and tolerability are examined. In the last part of the article there is an outline of the project formulated for the development in Sicily in the province of Enna where NegEnt is produced in accordance with an innovative project of regional social promotion and based on the cultivation of Cannabis Sativa Light, otherwise known as Progetto Demetra. This project established an operational module that is managed by a non-profit social enterprise called the Higher Institute for Cognitive Sciences, the ALETEIA Institute of Therapeutic Cannabis, and as an ethical enterprise, which is called Herbal Neurocare (registered name and trademark).It contributes to improved health as well as promoting the economic and social development of this economically depressedarea.